Translational Medicine Strategies in PTSD Drug Development

Dan J. Stein, Willie Daniels, Brian H. Harvey

Research output: Chapter in Book/Report/Conference proceedingChapterpeer-review

Abstract

Once considered a normal response to an abnormal traumatic event, posttraumatic stress disorder (PTSD) has been reconceptualized in terms of unusual persistence of fear-conditioned responses. Selective serotonin reuptake inhibitors (SSRIs) have been registered for the treatment of this condition, but they are efficacious in only some patients, and effect sizes for treatment response are relatively low. The ready availability of animal models of fear conditioning, expression, and extinction, together with advances in human studies of the neurocircuitry and neurogenetics of PTSD, potentially paves the way for a translational approach to developing medications for the prevention and treatment of this disorder. Here, we review translational work being undertaken in PTSD, describing some of its presumptive potential, as well as some possible pitfalls.

Original languageEnglish
Title of host publicationHandbook of Behavioral Neuroscience
PublisherElsevier B.V.
Pages375-382
Number of pages8
DOIs
StatePublished - 2019
Externally publishedYes

Publication series

NameHandbook of Behavioral Neuroscience
Volume29
ISSN (Print)1569-7339

Keywords

  • Fear
  • Pharmacotherapy
  • Posttraumatic stress disorder
  • SSRI
  • Translational neuroscience

Fingerprint

Dive into the research topics of 'Translational Medicine Strategies in PTSD Drug Development'. Together they form a unique fingerprint.

Cite this